CMND

Milestone advances Clearmind's clinical program as the company continues to develop CMND‑100 as a potential novel therapeutic candidate for alcohol use disorder

Published patent application covers 3-MMC-based treatment of dyskinesia, including in combination with Palmitoylethanolamide (PEA) Vancouver, Canada, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “ Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment  of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the publication of a patent application in Japan covering novel compositions and methods for treating dyskinesia, a neurological movement disorder characterized by involuntary movements. The published patent application covers the use of 3-Methylmethcathinone (“3-MMC”) for preventing, treating, or reducing dyskinesia symptoms, including pharmaceutical compositions comprising 3-MMC.

Company Calls for Consideration of New Regulatory Pathways and Cost Saving of Non-Hallucinogenic Neuroplastogens for Alcohol Use Disorder

The U.S. patent applications cover proprietary combinations of NeuroThera's PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, such as depression and PTSD as well as substance use disorders   Toronto, Ontario – TheNewswire - September 23, 2026 – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage pharmaceutical company, today highlighted the expansion of the U.S. intellectual property portfolio through its ongoing collaboration with Clearmind Medicine Inc. (“ Clearmind ”) (Nasdaq: CMND).

The covered applications address potential therapeutic uses across a range of indications, including mental health disorders, such as depression and PTSD as well as substance use disorders

VANCOUVER, BC September 17, 2026 - TheNewswire — StickIt Technologies Inc. (CSE: STKT) (the "Company" or "StickIt"), a developer and patent holder of proprietary cannabinoid and plant extract delivery technologies, today provides a comprehensive corporate update regarding leadership changes, recent financial transactions including loan acquisitions and private placements, and developments across its international intellectual property portfolio.    CHANGES TO BOARD OF DIRECTORS AND EXECUTIVE MANAGEMENT

Mary-Elizabeth Gifford, Chief of Global Impact at Clearmind Medicine, spoke on patient access and shared insights from Clearmind's clinical trial at Yale and Johns Hopkins

Vancouver, Canada, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment  of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the enrollment of the first patients with Alcohol Use Disorder (“AUD”) in its ongoing clinical trial evaluating CMND-100, the Company's proprietary psychedelic-based treatment candidate for AUD.

Vancouver, Canada, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company” or “Clearmind”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment  of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced that the Yale University's IRB has approved the initiation of patient recruitment for Parts B and C of its Phase I/II clinical trial evaluating CMND‑100.

Charging Robotics  is one of the few worldwide developing innovative wireless charging systems designed specifically for automated parking facilities and autonomous mobile platforms- environments where conventional cables and plug-in infrastructure cannot operate.